A century and a half ago, people turned to be seized with panic at the mention of epidemic diseases such as tuberculosis, cholera and diphtheria, etc. Today, with the invention of antibiotics, these epidemic diseases have already lost their past “ferocious faces”. However, some chronic and viral diseases like cancer, hepatitis, AIDS and avian influenza have been severely threatening human life and health. For a long period of time, people have been longing for innovative drugs to overcome these stubborn diseases.
The dream is now turning into a reality.The R & D team of Genova Biotech composed of prominent specialists has built a world-leading protein engineering technology platform and has successfully developed a highly potent anti-tumor and anti-virus protein drug, Novaferon, led by Dr. Longbin Liu, a well-known biologist. It is proven that the anti-tumor and anti-virus activities of Novaferon are more than 200 times and 10 times higher than that of similar products, respectively, which is absolutely unique worldwide. Relying on the two “crowns” in the field of biopharmaceuticals, Genova Biotech will be undoubtedly promoted to world pioneering biopharmaceutical enterprise.
China’s economy is experiencing an unprecedented boom. With the background of an urgent demand of hightech industries, the world-class protein engineering project of Genova Biotech lays a solid foundation for the rapid development of protein engineering technology in China. Recently, one of the national significant projects of new drugs creation, the ˘ń-class new biodrug --- Novaferon (Highly Potent Recombinant Anti-tumor and Anti-virus Protein Injection) has been granted the clinical approval (Clinical Lot: 2009L05468) by SFDA. Both Beijing municipal and Chaoyang district governments have been paying great attention to the project. Two years ago, the senior officials of the governments visited our biotech R & D center in North America, and they expressed their expectation to have the project and Genova Biotech relocated to China. With the efforts of both sidesŁ¬Genova Biotech has successfully settled down in Wangjing Science and Technology Park, Beijing.
Genova Biotech adopts an innovative business pattern with a strong integration of investment, management and technical contribution. This model maximizes the centralization of resources for technical innovation and product development, while minimizes potential risks that high-tech enterprises may encounter. The implementation of the pattern guarantees a stable management structure for Genova Biotech. The current development strategy of the company is to promote the manufacturing and commercialization of Noveferon, and to build a world-class biopharmaceutical group with the integration of protein engineering research, development, production and marketing. Furthermore, Genova Biotech endeavors to drive the development of regional biopharmaceutical industrial groups by continuing development of new protein drugs, which will eventually make China the global pacemaker in the areas of biotechnology and bio-economy.
The staffs of Genova Biotech are dedicated to brightening the future for those who are suffering from serious diseases. To improve the lives of people all over the world, is and will be the exclusive mission of Genova Biotech. It is the company’s permanent commitment to the world and the eternal driving force for our unremitting efforts.
The dream is now turning into a reality.The R & D team of Genova Biotech composed of prominent specialists has built a world-leading protein engineering technology platform and has successfully developed a highly potent anti-tumor and anti-virus protein drug, Novaferon, led by Dr. Longbin Liu, a well-known biologist. It is proven that the anti-tumor and anti-virus activities of Novaferon are more than 200 times and 10 times higher than that of similar products, respectively, which is absolutely unique worldwide. Relying on the two “crowns” in the field of biopharmaceuticals, Genova Biotech will be undoubtedly promoted to world pioneering biopharmaceutical enterprise.
China’s economy is experiencing an unprecedented boom. With the background of an urgent demand of hightech industries, the world-class protein engineering project of Genova Biotech lays a solid foundation for the rapid development of protein engineering technology in China. Recently, one of the national significant projects of new drugs creation, the ˘ń-class new biodrug --- Novaferon (Highly Potent Recombinant Anti-tumor and Anti-virus Protein Injection) has been granted the clinical approval (Clinical Lot: 2009L05468) by SFDA. Both Beijing municipal and Chaoyang district governments have been paying great attention to the project. Two years ago, the senior officials of the governments visited our biotech R & D center in North America, and they expressed their expectation to have the project and Genova Biotech relocated to China. With the efforts of both sidesŁ¬Genova Biotech has successfully settled down in Wangjing Science and Technology Park, Beijing. Genova Biotech adopts an innovative business pattern with a strong integration of investment, management and technical contribution. This model maximizes the centralization of resources for technical innovation and product development, while minimizes potential risks that high-tech enterprises may encounter. The implementation of the pattern guarantees a stable management structure for Genova Biotech. The current development strategy of the company is to promote the manufacturing and commercialization of Noveferon, and to build a world-class biopharmaceutical group with the integration of protein engineering research, development, production and marketing. Furthermore, Genova Biotech endeavors to drive the development of regional biopharmaceutical industrial groups by continuing development of new protein drugs, which will eventually make China the global pacemaker in the areas of biotechnology and bio-economy.
The staffs of Genova Biotech are dedicated to brightening the future for those who are suffering from serious diseases. To improve the lives of people all over the world, is and will be the exclusive mission of Genova Biotech. It is the company’s permanent commitment to the world and the eternal driving force for our unremitting efforts.